pCPAO

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The November 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Four new drug products have initiated pCPA negotiations, for a total of 39 active negotiations; Eleven negotiations have been completed/closed, for a total of 188 joint completed/closed negotiations; and One new drug product was added to…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The October 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Two new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; Seven negotiations have been completed/closed, for a total of 177 joint completed/closed negotiations; and No new drug products were added to…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The September 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Six new drug products have initiated pCPA negotiations, for a total of 51 active negotiations; Two negotiations have been completed/closed, for a total of 170 joint completed/closed negotiations; and One new drug product was added to…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The August 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Six new drug products have initiated pCPA negotiations, for a total of 47 active negotiations; Five negotiations have been completed, for a total of 168 joint negotiations; and One new drug product was added to the…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The latest update as of July 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO update are as follows: Seven new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations Three negotiations have been completed since the last update, for a total of 163 joint…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Updates   The latest update as of June 30, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO update are as follows: Six new drug products have initiated pCPA negotiations since the last update, for a total of 42 active negotiations Seven negotiations have been completed since the last update, for a total of 160 joint…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Updates   The latest update as of May 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows: Nine new drug products have initiated pCPA negotiations since the last update, for a total of 43 active negotiations Four negotiations have been completed since the last update, for a total of 153 joint negotiations. No new drug…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The latest update as of April 30, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows: Nine new products have initiated pCPA negotiations since the last update, for a total of 38 active negotiations: Cosentyx (secukinumab) – psoriatic arthritis Cosentyx (secukinumab) – ankylosing spondylitis Erelzi (etanercept) – ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The latest update as of March 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows: Three new products have initiated pCPA negotiations since the last update, for a total of 30 active negotiations: Afinitor (everolimus) for a new indication - treatment of neuroendocrine tumours of gastrointestinal or lung origin Campral (acamprosate calcium) used…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) updated the status of negotiations on brand name drugs as of February 28, 2017. There are currently 33 negotiations underway with one new file – Eylea (aflibercept) was added since the last update on January 31, 2017. There have been 142 joint negotiations completed with 8 files successfully negotiated since the last update of January 31, 2017: Daklinza…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) updated the status of negotiations on brand name drugs as of January 31, 2017. There are currently 38 negotiations underway with one new file (Keytruda (pembrolizumab)) added since the last update on December 31, 2016. There have been 133 joint negotiations completed with 2 files successfully negotiated since the last update of December 31, 2016: Blincyto…